The role of low-dose glucocorticoids for rheumatoid arthritis in the biologic era

Clinical and Experimental Rheumatology

Volumn 31, Issue SUPPL.78, 2013, Pages

  Caporali, Roberto ^a   Scirè, Carlo Alberto ^b   Todoerti, Monica ^a   Montecucco, Carlomaurizio ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b Epidemiology Unit   (Italy)

Author keywords

Biologics; Discontinuation; Glucocorticoid; Remission; Rheumatoid arthritis

Indexed keywords

ABATACEPT; ADALIMUMAB; BIOLOGICAL PRODUCT; CERTOLIZUMAB PEGOL; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GLUCOCORTICOID; GOLIMUMAB; INFLIXIMAB; METHOTREXATE; PREDNISONE; RITUXIMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ARTICLE; CATARACT; DIABETES MELLITUS; DRUG COST; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; HYPERTENSION; INFECTION; LOW DRUG DOSE; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; GLUCOCORTICOIDS; HUMANS; RECURRENCE; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 84885702552     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. SAAG KG, CRISWELL LA, SEMS KM, NETTLEMAN MD, KOLLURI S: Low-dose corticosteroids in rheumatoid arthritis. A metaanalysis of their moderate-term effectiveness. Arthritis Rheum 1996; 39: 1818-25.
2. CAPORALI R, TODOERTI M, SAKELLARIOU G, MONTECUCCO C: Glucocorticoids in rheumatoid arthritis. Drugs 2013; 73: 31-43.
3. JACOBS JWG: The CAMERA (Computer- Assisted Management in Early Rheumatoid Arthritis) studies. Clin Exp Rheumatol 2012; 30 (Suppl. 73): S39-43.
4. SVENSSON B, HAFSTRöM I: Effects on joint destruction and remission, bone turnover and lack of influence on atherogenesis: a review of the BARFOT low-dose prednisolone studies on patients with early RA. Clin Exp Rheumatol 2011; 29 (Suppl. 68): S63-67.
5. MONTECUCCO C, TODOERTI M, SAKELLARIOU G, SCIRÈ CA, CAPORALI R: Lowdose oral prednisone improves clinical and ultrasonographic remission rates in early rheumatoid arthritis: results of a 12-month open-label randomised study. Arthritis Res Ther 2012; 14: R112.
6. TODOERTI M, SCIRÈ CA, BOFFINI N, BUGATTI S, MONTECUCCO C, CAPORALI R: Early disease control by low-dose prednisone comedication may affect the quality of remission in patients with early rheumatoid arthritis. Ann N Y Acad Sci 2010; 1193: 139-45.
7. SCIRÈ CA, MONTECUCCO C, CODULLO V, EPIS O, TODOERTI M, CAPORALI R: Ultrasonographic evaluation of joint involvement in early rheumatoid arthritis in clinical remission: power Doppler signal predicts shortterm relapse. Rheumatology (Oxford) 2009; 48: 1092-7.
8. SAKELLARIOU G, SCIRÈ CA, VERSTAPPEN SMM, MONTECUCCO C, CAPORALI R: In patients with early rheumatoid arthritis, the new ACR/EULAR definition of remission identifies patients with persistent absence of functional disability and suppression of ultrasonographic synovitis. Ann Rheum Dis 2013; 72: 245-9.
9. SCIRÈ CA, VERSTAPPEN SMM, MIRJAFARI H et al.: Reduction of long-term disability in inflammatory polyarthritis by early and persistent suppression of joint inflammation: results from the Norfolk Arthritis Register. Arthritis Care Res 2011; 63: 945-52.
10. KIRWAN JR, BIJLSMA JWJ, BOERS M, SHEA BJ: Effects of glucocorticoids on radiological progression in rheumatoid arthritis. Cochrane Database Syst Rev 2007; 1: CD006356.
11. GRAUDAL N, JüRGENS G: Similar effects of disease-modifying antirheumatic drugs, glucocorticoids, and biologic agents on radiographic progression in rheumatoid arthritis: meta-analysis of 70 randomized placebo-controlled or drug-controlled studies, including 112 comparisons. Arthritis Rheum 2010; 62: 2852-63.
12. MALYSHEVA O, BAERWALD CG: Low-dose corticosteroids and disease modifying drugs in patients with rheumatoid arthritis. Clin Exp Rheumatol 2011; 29 (Suppl. 68): S113-115.
13. CHOY EH, KINGSLEY GH, KHOSHABA B, PIPITONE N, SCOTT DL, Intramuscular Methylprednisolone Study Group: A two year randomised controlled trial of intramuscular depot steroids in patients with established rheumatoid arthritis who have shown an incomplete response to disease modifying antirheumatic drugs. Ann Rheum Dis 2005; 64: 1288-93.
14. SMOLEN JS, LANDEWé R, BREEDVELD FC et al.: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010; 69: 964-75.
15. GORTER SL: Rheumatoid arthritis and glucocorticoids; the contribution of a literature search to the development of a EULAR recommendation on treatment with glucocorticoids in RA. Clin Exp Rheumatol 2011; 29 (Suppl. 68): S77-80.
16. SOKKA T, KAUTIAINEN H, TOLOZA S et al.: QUEST-RA: quantitative clinical assessment of patients with rheumatoid arthritis seen in standard rheumatology care in 15 countries. Ann Rheum Dis 2007; 66: 1491-6.
17. PINCUS T, SOKKA T, CASTREJóN I, CUTOLO M: Decline of mean initial prednisone dosage from 10.3 to 3.6 mg/day to treat rheumatoid arthritis between 1980 and 2004 in one clinical setting, with long-term effectiveness of dosages less than 5 mg/day. Arthritis Care Res 2013; 65: 729-36.
18. Da SILVA JAP: Safety of glucocorticoids - clinical trials. Clin Exp Rheumatol 2011; 29 (Suppl. 68): S99-103.
19. ANDRé V, le GOFF B, LEUX C, POT-VAUCEL M, MAUGARS Y, BERTHELOT J-M: Information on glucocorticoid therapy in the main studies of biological agents. Joint Bone Spine 2011; 78: 478-83.
20. CAPORALI R, CAPRIOLI M, BOBBIO-PALLAVICINI F, MONTECUCCO C: DMARDS and infections in rheumatoid arthritis. Autoimmun Rev 2008; 8: 139-43.
21. DIXON WG, SUISSA S, HUDSON M: The association between systemic glucocorticoid therapy and the risk of infection in patients with rheumatoid arthritis: systematic review and meta-analyses. Arthritis Res Ther 2011; 13: R139.
22. STRANGFELD A, EVESLAGE M, SCHNEIDER M et al.: Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? Ann Rheum Dis 2011; 70: 1914-20.
23. GALLOWAY JB, HYRICH KL, MERCER LK et al.: Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford) 2011 1; 50: 124-31.
24. MARCHESONI A, ZACCARA E, GORLA R et al.: TNF-a antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice. Ann N Y Acad Sci 2009; 1173: 837-46.
25. SOKKA T, PINCUS T: Rheumatoid arthritis: strategy more important than agent. Lancet 2009; 374: 430-2
26. van den BROEK M, LEMS WF, ALLAART CF: BeSt practice: the success of early-targeted treatment in rheumatoid arthritis. Clin Exp Rheumatol 2012; 30 (Suppl. 73): S35-38.
27. BYKERK VP, KEYSTONE EC, KURIYA B, LARCHé M, THORNE JC, HARAOUI B: Achieving remission in clinical practice: lessons from clinical trial data. Clin Exp Rheumatol 2013; 31: 621-32.
28. van den BROEK M, LEMS WF, ALLAART CF: Do we need guidelines to stop as well as to start biological therapies for rheumatoid arthritis? Clin Exp Rheumatol 2012; 30 (Suppl. 73): S21-26.
29. YOSHIDA K, SUNG Y-K, KAVANAUGH A et al.: Biologic discontinuation studies: a systematic review of methods. Ann Rheum Dis 2013 May 30 [Epub ahead of print].
30. TANAKA Y, TAKEUCHI T, MIMORI T et al.: Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study. Ann Rheum Dis 2010; 69: 1286-91.
31. HARIGAI M, TAKEUCHI T, TANAKA Y, MATSUBARA T, YAMANAKA H, MIYASAKA N: Discontinuation of adalimumab treatment in rheumatoid arthritis patients after achieving low disease activity. Mod Rheumatol 2012; 22: 814-22.
32. KAVANAUGH A, EMERY P, FLEISCHMANN R et al.: Withdrawal of adalimumab in early rheumatoid arthritis patients who attained stable low disease activity with adalimumab plus methotrexate: results of a phase 4, double- blind, placebo-controlled trial. Rheumatology (Oxford) 2012; 51: 29-30.
33. NISHIMOTO N, AMANO K, HIRABAYASHI Y et al.: Drug free REmission/low disease activity after cessation of tocilizumab (Actemra) Monotherapy (DREAM) study. Mod Rheumatol 2013 May 3 [Epub ahead of print].
34. AGUILAR-LOZANO L, CASTILLO-ORTIZ JD, VARGAS-SERAFIN C et al.: Sustained clinical remission and rate of relapse after tocilizumab withdrawal in patients with rheumatoid arthritis. J Rheumatol 2013; 40: 1069-73.
35. SMOLEN JS, NASH P, DUREZ P et al.: Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet 2013; 381: 918-29.
36. SMOLEN J, EMERY P, FERRACCIOLI G et al.: Maintenance of remission in ra patients with low to moderate disease activity following withdrawal of CertolizumabPegol treatment: week 52 results from the certain study. Rheumatology (Oxford) 2013; 52: 85.
37. DETERT J, BASTIAN H, LISTING J et al.: Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study. Ann Rheum Dis 2013; 72: 844-50.
38. CHATZIDIONYSIOU K, TURESSON C, TELEMAN A et al.: A multicenter, randomized, controlled, open-label pilot study of the feasibility of discontinuation of adalimumab in rheumatoid arthritis patients in stable clinical remission. Arthritis Rheum 2012; 64: S336
39. van VOLLENHOVEN RF, OSTERGAARD M, LEIRISALO-REPO M et al.: In rheumatoid arthritis patients with stable low disease activity on methotrexate plus etanercept, continuation of etanercept 50 mg weekly or. Arthritis Rheum 2012; 64: 4171.
40. TANAKA Y, HIRATA S, FUKUYO S et al.: Discontinuation of adalimumab without functional and radiographic damage progression after achieving sustained remission in patients with rheumatoid arthritis (the HONOR study): 1-year results. Arthritis Rheum 2012; 64: S333.
41. van der MAAS A, KIEVIT W, van den BEMT BJF, van den HOOGEN FHJ, van RIEL PL, den BROEDER AA: Down-titration and discontinuation of infliximab in rheumatoid arthritis patients with stable low disease activity and stable treatment: an observational cohort study. Ann Rheum Dis 2012; 71: 1849-54.
42. van den BROEK M, KLARENBEEK NB, DIRVEN L et al.: Discontinuation of infliximab and potential predictors of persistent low disease activity in patients with early rheumatoid arthritis and disease activity score-steered therapy: subanalysis of the BeSt study. Ann Rheum Dis 2011; 70: 1389-94.
43. KAINE J, GLADSTEIN G, STRUSBERG I et al.: Evaluation of abatacept administered subcutaneously in adults with active rheumatoid arthritis: impact of withdrawal and reintroduction on immunogenicity, efficacy and safety (phase IIIb ALLOW study). Ann Rheum Dis 2012; 71: 38-44.
44. SALEEM B, KEEN H, GOEB V et al.: Patients with RA in remission on TNF blockers: when and in whom can TNF blocker therapy be stopped? Ann Rheum Dis 2010; 69: 1636-42.
45. BROCQ O, MILLASSEAU E, ALBERT C et al.: Effect of discontinuing TNF alpha antagonist therapy in patients with remission of rheumatoid arthritis. Joint Bone Spine 2009; 76: 350-55.
46. QUINN MA, CONAGHAN PG, O'CONNOR PJ et al.: Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal-Results from a twelvemonth randomized, double-blind, placebocontrolled trial. Arthritis Rheum 2005; 52: 27-35.
47. BUCH MH, MARZO-ORTEGA H, BINGHAM SJ, EMERY P: Long-term treatment of rheumatoid arthritis with tumour necrosis factor alpha blockade: outcome of ceasing and restarting biologicals. Rheumatology (Oxford) 2004; 43: 243-4.